UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 353

Sortiert nach

Randomised clinical trial: individualised vs. weight‐based dosing of azathioprine in Crohn's disease

Alimentary pharmacology & therapeutics, 2014-01, Vol.39 (2), p.163-175

2014

Volltextzugriff (PDF)

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

Gastroenterology (New York, N.Y. 1943), 2000-04, Vol.118 (4), p.705-713

2000

Volltextzugriff (PDF)

Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes

Alimentary pharmacology & therapeutics, 2007-10, Vol.26 (7), p.1005-1018

2007

Volltextzugriff (PDF)

A validated web‐based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables

Alimentary pharmacology & therapeutics, 2016-01, Vol.43 (2), p.262-271

2016

Volltextzugriff (PDF)

Editorial: how to interpret risks and prediction of complications in Crohn's disease – can our patients interpret them? Authors' reply

Alimentary pharmacology & therapeutics, 2016-03, Vol.43 (5), p.653-653

2016

Volltextzugriff (PDF)

Serum Immune Responses Predict Rapid Disease Progression among Children with Crohn's Disease: Immune Responses Predict Disease Progression

The American journal of gastroenterology, 2006-02, Vol.101 (2), p.360-367

2006

Volltextzugriff (PDF)

New patients: should children be treated differently?

Colorectal disease, 2006-05, Vol.8 (s1), p.15-19

Dubinsky, M. C.

2006

Volltextzugriff (PDF)

Exploring Disease Remission and Bowel Urgency Severity Among Adults with Moderate to Severe Ulcerative Colitis: A Qualitative Study

Patient related outcome measures, 2022-01, Vol.13, p.287-300

2022

Volltextzugriff (PDF)

Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2021-10, Vol.161 (4), p.1340-1343.e2

2021

Volltextzugriff (PDF)

Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2022-08, Vol.20 (8), p.1881-1883.e1

2022

Volltextzugriff (PDF)

P381 Ustekinumab trough levels are associated with sonographic transmural healing in Pediatric Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i515-i517

2023

Volltextzugriff (PDF)

Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease

The American journal of gastroenterology, 2001-03, Vol.96 (3), p.758-765

2001

Volltextzugriff (PDF)

An open‐label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6‐mercaptopurine therapy

Inflammatory bowel diseases, 2001-08, Vol.7 (3), p.181-189

2001

Volltextzugriff (PDF)

P956 Pregnancy outcomes after maternal or paternal exposure in the tofacitinib ulcerative colitis clinical programme

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1735-i1736

2024

Volltextzugriff (PDF)

Pneumatosis intestinalis and colocolic intussusception complicating Crohn's disease

Journal of pediatric gastroenterology and nutrition, 2000, Vol.30 (1), p.96-98

2000

Volltextzugriff (PDF)

Fecal IgA Levels Are Determined by Strain-Level Differences in Bacteroides ovatus and Are Modifiable by Gut Microbiota Manipulation

Cell host & microbe, 2020-03, Vol.27 (3), p.467-475.e6

2020

Volltextzugriff (PDF)

P759 Understanding how patients with moderate-to-severe Crohn’s disease describe the spectrum of bowel urgency definitions: Results from qualitative research

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1415-i1416

2024

Volltextzugriff (PDF)

P1040 Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn’s disease: a matching-adjusted indirect comparison

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1875-i1876

2024

Volltextzugriff (PDF)

P720 Exit interviews exploring Crohn’s disease patients’ experience of changes in their bowel urgency during the mirikizumab Phase 3 clinical trial in adult patients with moderate to severe Crohn disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1353-i1354

2024

Volltextzugriff (PDF)

P138 Psychometric validation and interpretation of a patient-reported outcomes instrument to assess bowel urgency among adults with moderate to severe Ulcerative Colitis

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i220-i222

2022

Volltextzugriff (PDF)

P186 Impact of tofacitinib maintenance therapy on key Ulcerative Colitis patient-reported outcomes of fatigue, urgency, abdominal pain and sexual dysfunction using IBDQ and SF-36 individual items as proxies

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i339-i342

2023

Volltextzugriff (PDF)

DOP70 Prevalence and severity of bowel urgency in Crohn’s Disease: Results from the Communicating Needs and Features of IBD Experience (CONFIDE) Survey

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i201-i202

2024

Volltextzugriff (PDF)

P983 Treatment of patients with moderate-to-severe Crohn’s disease with subcutaneous infliximab leads to an endoscopic response across all segments of the colon and terminal ileum: A post hoc analysis of the LIBERTY-CD study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1782-i1783

2024

Volltextzugriff (PDF)

P568 Clinical relevance of baseline and change in Urgency Numeric Rating Scale score for mirikizumab treatment for Ulcerative Colitis

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1109-i1111

2024

Volltextzugriff (PDF)

1 – 25 von 353

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(335)
Mit Volltextzugriff
(277)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Randomised clinical trial: individualised vs. weight‐based dosing of azathioprine in Crohn's disease

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes

A validated web‐based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables

Editorial: how to interpret risks and prediction of complications in Crohn's disease – can our patients interpret them? Authors' reply

Serum Immune Responses Predict Rapid Disease Progression among Children with Crohn's Disease: Immune Responses Predict Disease Progression

New patients: should children be treated differently?

Exploring Disease Remission and Bowel Urgency Severity Among Adults with Moderate to Severe Ulcerative Colitis: A Qualitative Study

Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases

P381 Ustekinumab trough levels are associated with sonographic transmural healing in Pediatric Inflammatory Bowel Disease

Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease

An open‐label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6‐mercaptopurine therapy

Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease

P956 Pregnancy outcomes after maternal or paternal exposure in the tofacitinib ulcerative colitis clinical programme

Pneumatosis intestinalis and colocolic intussusception complicating Crohn's disease

Fecal IgA Levels Are Determined by Strain-Level Differences in Bacteroides ovatus and Are Modifiable by Gut Microbiota Manipulation

P759 Understanding how patients with moderate-to-severe Crohn’s disease describe the spectrum of bowel urgency definitions: Results from qualitative research

P1040 Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn’s disease: a matching-adjusted indirect comparison

P720 Exit interviews exploring Crohn’s disease patients’ experience of changes in their bowel urgency during the mirikizumab Phase 3 clinical trial in adult patients with moderate to severe Crohn disease

P138 Psychometric validation and interpretation of a patient-reported outcomes instrument to assess bowel urgency among adults with moderate to severe Ulcerative Colitis

P186 Impact of tofacitinib maintenance therapy on key Ulcerative Colitis patient-reported outcomes of fatigue, urgency, abdominal pain and sexual dysfunction using IBDQ and SF-36 individual items as proxies

DOP70 Prevalence and severity of bowel urgency in Crohn’s Disease: Results from the Communicating Needs and Features of IBD Experience (CONFIDE) Survey

P983 Treatment of patients with moderate-to-severe Crohn’s disease with subcutaneous infliximab leads to an endoscopic response across all segments of the colon and terminal ileum: A post hoc analysis of the LIBERTY-CD study

P568 Clinical relevance of baseline and change in Urgency Numeric Rating Scale score for mirikizumab treatment for Ulcerative Colitis

Suchergebnisse filtern